{"Title":"ARMO BioSciences","Industry":"PHARMACEUTICAL PREPARATIONS","Employees":"21","Founded":"","Address":"","Phone":"(650) 779-5075","Web_address":"http://www.armobio.com","Market_cup":"$497.7mil","Revenues":"$0 mil (last 12 months)","Net_income":"$-39.6 mil (last 12 months)","Symbol":"ARMO","Exchange":"NASDAQ","Shares":"7.5","Price_range":"$17.00 - $17.00","Est_volume":"$128.0 mil","Manager":"Jefferies/ Leerink Partners/ BMO Capital Markets","CO_managers":"Baird","Exp_to_trade":"1/26/2018","Status":"","Quiet_period":"Available only to Subscribers","Lock_up_period":"Available only to Subscribers","Scoop_rate":"Available only to Subscribers","Rating_change":"Available only to Subscribers","Business":"We are a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates that activate the immune system of cancer patients to recognize and eradicate tumors. Our vision is to improve and prolong the lives of cancer patients by advancing and expanding the field of immuno-oncology through novel combinations and treatment sequences of our pipeline products with standard of care chemotherapies and checkpoint inhibitors or with other emerging immunotherapies that elicit complementary and synergistic treatment effects."}